NCT06980038
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06980038
Title Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care RECRUITING Irvine California 92612 United States Details
UC Irvine Health/Chao Family Comprehensive Cancer Center RECRUITING Orange California 92868 United States Details
Emory University Hospital Midtown RECRUITING Atlanta Georgia 30308 United States Details
Ochsner Medical Center Jefferson RECRUITING New Orleans Louisiana 70121 United States Details
VCU Massey Comprehensive Cancer Center RECRUITING Richmond Virginia 23298 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field